دورية أكاديمية
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.
| العنوان: | Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine. |
|---|---|
| المؤلفون: | Feng Y; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA., Yuan M; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA., Powers JM; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Hu M; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA., Munt JE; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Arunachalam PS; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA., Leist SR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Bellusci L; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Kim J; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Adams LE; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Sundaramurthy S; Sino Biological US Inc., Wayne, PA 19087, USA., Zhu X; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA., Shirreff LM; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Mallory ML; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Scobey TD; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Moreno A; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA., O'Hagan DT; GSK, Rockville, MD 20850, USA., Kleanthous H; Bill and Melinda Gates Foundation, Seattle, WA 98109, USA., Villinger FJ; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA., King NP; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Suthar MS; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA 30329, USA., Khurana S; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Wilson IA; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA., Pulendran B; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA.; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA. |
| المصدر: | Science translational medicine [Sci Transl Med] 2023 May 10; Vol. 15 (695), pp. eadg7404. Date of Electronic Publication: 2023 May 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, DC : American Association for the Advancement of Science |
| مواضيع طبية MeSH: | Severe acute respiratory syndrome-related coronavirus* , COVID-19*/prevention & control, Animals ; Humans ; Mice ; Broadly Neutralizing Antibodies ; COVID-19 Vaccines ; Macaca ; SARS-CoV-2 ; Immunization ; Vaccination ; Antibodies, Monoclonal ; Antibodies, Viral ; Antibodies, Neutralizing |
| مستخلص: | The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development of countermeasures that provide broad protection against SARS-CoV-2 and related sarbecoviruses. Here, we identified extremely potent monoclonal antibodies (mAbs) that neutralized multiple sarbecoviruses from macaques vaccinated with AS03-adjuvanted monovalent subunit vaccines. Longitudinal analysis revealed progressive accumulation of somatic mutation in the immunoglobulin genes of antigen-specific memory B cells (MBCs) for at least 1 year after primary vaccination. Antibodies generated from these antigen-specific MBCs at 5 to 12 months after vaccination displayed greater potency and breadth relative to those identified at 1.4 months. Fifteen of the 338 (about 4.4%) antibodies isolated at 1.4 to 6 months after the primary vaccination showed potency against SARS-CoV-2 BA.1, despite the absence of serum BA.1 neutralization. 25F9 and 20A7 neutralized authentic clade 1 sarbecoviruses (SARS-CoV, WIV-1, SHC014, SARS-CoV-2 D614G, BA.1, and Pangolin-GD) and vesicular stomatitis virus-pseudotyped clade 3 sarbecoviruses (BtKY72 and PRD-0038). 20A7 and 27A12 showed potent neutralization against all SARS-CoV-2 variants and multiple Omicron sublineages, including BA.1, BA.2, BA.3, BA.4/5, BQ.1, BQ.1.1, and XBB. Crystallography studies revealed the molecular basis of broad and potent neutralization through targeting conserved sites within the RBD. Prophylactic protection of 25F9, 20A7, and 27A12 was confirmed in mice, and administration of 25F9 particularly provided complete protection against SARS-CoV-2, BA.1, SARS-CoV, and SHC014 challenge. These data underscore the extremely potent and broad activity of these mAbs against sarbecoviruses. |
| References: | Immunity. 2021 Aug 10;54(8):1853-1868.e7. (PMID: 34331873) Cell. 2020 Nov 12;183(4):1070-1085.e12. (PMID: 33031744) Nature. 2022 Feb;602(7898):664-670. (PMID: 35016195) Vaccine. 2015 Jul 31;33(32):3953-62. (PMID: 26093202) N Engl J Med. 2022 Aug 4;387(5):468-470. (PMID: 35857646) Cell. 2021 Oct 14;184(21):5432-5447.e16. (PMID: 34619077) N Engl J Med. 2022 Oct 6;387(14):1332-1333. (PMID: 36103455) Nat Commun. 2022 May 27;13(1):2979. (PMID: 35624101) Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507) Science. 2022 Aug 12;377(6607):735-742. (PMID: 35857703) Science. 2020 Aug 28;369(6507):1119-1123. (PMID: 32661058) Science. 2021 Aug 27;373(6558):991-998. (PMID: 34214046) Science. 2022 Aug 5;377(6606):eabq0839. (PMID: 35857620) Nat Rev Drug Discov. 2021 Jun;20(6):454-475. (PMID: 33824489) Nature. 2023 Feb;614(7948):521-529. (PMID: 36535326) Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645) Ann Rheum Dis. 2022 Jul;81(7):1044-1045. (PMID: 35144925) Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. (PMID: 20057044) Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17957-17964. (PMID: 32661157) Sci Transl Med. 2020 Jul 1;12(550):. (PMID: 32513867) Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2205784119. (PMID: 35767670) N Engl J Med. 2012 Nov 8;367(19):1814-20. (PMID: 23075143) Cell. 2023 Jan 19;186(2):279-286.e8. (PMID: 36580913) Nat Immunol. 2021 Nov;22(11):1452-1464. (PMID: 34611361) Science. 2022 Nov 11;378(6620):619-627. (PMID: 36264829) J Immunol Methods. 2012 Dec 14;386(1-2):85-93. (PMID: 22989932) Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199) Sci Transl Med. 2022 Aug 17;14(658):eabq4130. (PMID: 35976993) Science. 2021 Feb 19;371(6531):823-829. (PMID: 33495307) Nature. 2021 Jun;594(7862):253-258. (PMID: 33873199) Nature. 2013 Nov 28;503(7477):535-8. (PMID: 24172901) Methods Enzymol. 1997;276:307-26. (PMID: 27754618) Nature. 2022 Aug;608(7923):593-602. (PMID: 35714668) Sci Immunol. 2021 Feb 23;6(56):. (PMID: 33622975) Cell. 2020 Nov 12;183(4):1058-1069.e19. (PMID: 33058755) N Engl J Med. 2003 May 15;348(20):1967-76. (PMID: 12690091) Science. 2011 Aug 12;333(6044):843-50. (PMID: 21737702) Nature. 2021 Sep;597(7874):97-102. (PMID: 34261126) Nature. 2021 Sep;597(7874):103-108. (PMID: 34280951) Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8. (PMID: 18503082) Science. 2020 May 8;368(6491):630-633. (PMID: 32245784) Sci Transl Med. 2010 Jan 20;2(15):15ra5. (PMID: 20371470) Sci Transl Med. 2022 Aug 10;14(657):eabl9605. (PMID: 35947674) NPJ Vaccines. 2018 Oct 1;3:40. (PMID: 30302282) J Mol Biol. 2007 Sep 21;372(3):774-97. (PMID: 17681537) Science. 2021 Sep 03;373(6559):1109-1116. (PMID: 34344823) Science. 2022 Aug 12;377(6607):728-735. (PMID: 35857439) Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448) Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53. (PMID: 26976607) Cell Rep. 2022 Nov 15;41(7):111650. (PMID: 36335937) NPJ Vaccines. 2021 Dec 21;6(1):158. (PMID: 34934069) Nature. 2021 Mar;591(7851):639-644. (PMID: 33461210) Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002) Adv Virus Res. 2019;105:93-116. (PMID: 31522710) Science. 2020 Nov 20;370(6519):950-957. (PMID: 32972994) Nature. 2022 Mar;603(7903):913-918. (PMID: 35114688) N Engl J Med. 2022 Apr 7;386(14):1377-1380. (PMID: 35297591) Nat Microbiol. 2020 Nov;5(11):1408-1417. (PMID: 32724171) PLoS Pathog. 2007 Jan;3(1):e5. (PMID: 17222058) Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21. (PMID: 20124702) Nature. 2020 Oct;586(7830):560-566. (PMID: 32854108) Cell. 2021 Mar 4;184(5):1201-1213.e14. (PMID: 33571429) Nature. 2022 Apr;604(7904):141-145. (PMID: 35168246) Sci Transl Med. 2011 Jun 1;3(85):85ra48. (PMID: 21632986) Nat Med. 2015 Dec;21(12):1508-13. (PMID: 26552008) Nat Commun. 2023 Jan 12;14(1):189. (PMID: 36635284) Immunity. 2014 Dec 18;41(6):909-18. (PMID: 25526306) N Engl J Med. 2003 Dec 18;349(25):2431-41. (PMID: 14681510) J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. (PMID: 19461840) Immunity. 2021 Feb 9;54(2):355-366.e4. (PMID: 33484642) Nature. 2021 Dec;600(7889):530-535. (PMID: 34670266) Front Immunol. 2019 Oct 11;10:2426. (PMID: 31681312) |
| معلومات مُعتمدة: | DP1 AI158186 United States AI NIAID NIH HHS; P30 CA016086 United States CA NCI NIH HHS; INV-010680 United States GATES Bill & Melinda Gates Foundation; P30 GM133894 United States GM NIGMS NIH HHS; P01 AI167966 United States AI NIAID NIH HHS; P30 GM138396 United States GM NIGMS NIH HHS; INV-018675 United States GATES Bill & Melinda Gates Foundation; INV-004923 United States GATES Bill & Melinda Gates Foundation; 75N93022C00036 United States AI NIAID NIH HHS; U19 AI167903 United States AI NIAID NIH HHS |
| المشرفين على المادة: | 0 (Broadly Neutralizing Antibodies) 0 (COVID-19 Vaccines) 0 (Antibodies, Monoclonal) 0 (Antibodies, Viral) 0 (Antibodies, Neutralizing) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20230510 Date Completed: 20230512 Latest Revision: 20240511 |
| رمز التحديث: | 20240511 |
| مُعرف محوري في PubMed: | PMC11032722 |
| DOI: | 10.1126/scitranslmed.adg7404 |
| PMID: | 37163615 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1946-6242 |
|---|---|
| DOI: | 10.1126/scitranslmed.adg7404 |